MENU

Can Spero Therapeutics (SPRO) Stock Reach $5.30?

a developer of novel therapies for the treatment of resistant bacterial infections

A.I.Advisor
published price charts
A.I.Advisor
Nov 12, 2026

Can Spero Therapeutics (SPRO) Stock Reach $5.30?

Key Takeaways

  • The central target of $5.30 is the arithmetic mean of three verified analyst price targets—$4.00, $6.00, and $6.00—which average roughly $5.33 and are rounded to a clean level.
  • The latest verified price of about $1.02 would need to rise roughly 420% to reach $5.30, a very large move for a clinical-stage biopharmaceutical.
  • The analyst price target range is wide, from $4.00 to $6.00, reflecting genuine disagreement about the company's pipeline value.
  • Supporting factors include a cash runway into 2028, royalty and milestone revenue from its tebipenem program, and a pivot toward a new immune-mediated disease asset.
  • Principal risks include a stock down roughly 59% over the past year, mixed ratings that include a recent downgrade, and a small market capitalization of about $59 million.
  • For additional detail, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
  • You can also explore Trending AI Robots for automated market-monitoring tools.

Analyst Price Targets and Consensus View

Spero Therapeutics, Inc. (SPRO) is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company, not an ETF. Sell-side coverage is thin and, at times, inconsistent across data providers, so the figure below reflects individual, attributable targets rather than any single website's headline consensus.

The most recent, verifiable analyst price targets are $6.00 from Cantor Fitzgerald (analyst Kristen Kluska, who initiated coverage with an Overweight rating in late October 2026) and $6.00 from H.C. Wainwright (which maintained a Buy rating and raised its target from $5.00 in September 2026). S&P Global data via stock-analysis providers also lists a lower target of $4.00, giving a three-target range of $4.00 to $6.00. The arithmetic mean of these three targets is approximately $5.33, which rounds to the $5.30 central target used here.

Analyst opinion is split rather than uniformly bullish. Alongside the two Buy/Overweight ratings, Compass Point moved to Neutral and Zacks Research to Hold in September 2026, while Wall Street Zen downgraded the stock to Sell in late October 2026. Some aggregators therefore show a "Hold" consensus even as the published targets sit far above the market price—a sign of how disconnected the targets have become from current trading.

Current Market Position and Path Toward the Target

Spero shares closed near $1.02 in mid-November 2026, toward the bottom of a 52-week range of roughly $0.96 to $3.08. The market capitalization is approximately $59 million, even though the company reported about $50.8 million in cash and a net cash position near $48.7 million (roughly $0.84 per share). The gap between the current price and a $5.30 target is approximately 420%, which is a very large move by any standard and would require a fundamental repricing of the company's story rather than ordinary appreciation.

The stock has fallen about 59% over the past year and trades below both its 50-day and 200-day moving averages, indicating persistent selling pressure. For a $5.30 target to become relevant, investors would likely need to see the market re-rate Spero from a cash-and-royalty valuation toward a pipeline-option valuation.

What Could Support a Move Toward the Target

The clearest support is financial: Spero reported about $47 million in trailing revenue and $7.4 million in net income, driven by licensing, collaboration, and milestone arrangements. Its lead antibiotic asset, tebipenem HBr (an oral carbapenem for complicated urinary tract infections, licensed to GSK), has generated non-dilutive economics, including a $105 million royalty financing from HealthCare Royalty. Management has stated that cash is sufficient to fund operations into 2028, reducing near-term dilution risk.

Strategically, the company is pivoting beyond its legacy antibacterial franchise toward SP001, an anti-CD40L antibody in-licensed from Innovent and being developed for IgG4-related disease, with Phase 2 progression planned. Bulls argue the depressed share price undervalues the combination of net cash, royalty potential, and optionality from this new program.

What Could Prevent the Target From Being Reached

The obstacles are substantial. Clinical-stage programs carry high failure risk, and the SP001 pivot has not yet produced clinical proof-of-concept in its new indication. Revenue remains dependent on milestone and licensing payments that can be lumpy, and forward revenue-growth forecasts are negative in some models. The stock has also experienced material dilution, with shares outstanding rising about 9% over the past year.

Sentiment is decidedly mixed: a recent downgrade to Sell, Neutral and Hold ratings from other firms, and a price roughly 59% below its year-ago level all suggest institutional skepticism. A micro-cap stock trading near its 52-week low can remain disconnected from headline targets for long periods, and any pipeline setback could compress valuation further.

Technical Levels and Market Structure

The stock's most important level is its 52-week low of roughly $0.96, which has acted as a floor in recent sessions and represents a key support level. Below that, little durable support exists. On the upside, the 50-day moving average near $1.15 and the prior consolidation zone around $1.15 to $1.20 form an initial resistance level, followed by the 200-day moving average near $1.93. Reaching $5.30 would require clearing all of these and re-entering territory last seen before the stock's sharp 2026 decline—an extended, multi-stage move well beyond short-term technical momentum.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though the specific horizon for these targets was not uniformly disclosed and individual analysts may differ. The $4.00-to-$6.00 spread signals materially different assumptions about pipeline success. Investors should monitor upcoming quarterly results and guidance, updates on the SP001 Phase 2 program and any additional royalty or milestone payments, cash-burn trends and dilution, analyst revisions, and broad biotech risk appetite. Given the company's small size, changes in institutional positioning can move the stock sharply.

AI Daily Buy/Sell Signals

AI Daily Buy/Sell Signals from Tickeron use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single indicator or a fixed 12-month thesis, the system helps traders surface opportunities, track existing positions, and spot changing trends more efficiently. For a volatile micro-cap like SPRO, where price moves can be swift and sentiment-driven, tools that synthesize real-time technical and market data can be a useful complement to fundamental research.

Final Assessment

Can Spero Therapeutics (SPRO) reach $5.30? The target—the rounded mean of three verified analyst targets ranging from $4.00 to $6.00—implies a roughly 420% advance from about $1.02, a very large move. The case rests on net cash, royalty economics from the GSK-licensed tebipenem program, and optionality from the SP001 immune-mediated disease pivot. Against that stand a year-long downtrend, thin and divided analyst coverage that includes a recent downgrade, and a clinical-stage pipeline still awaiting proof-of-concept. Neither the support nor the risks justify a definitive conclusion; the next catalysts in earnings, pipeline updates, and analyst revisions will determine whether the gap between the share price and these elevated targets narrows.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

SPRO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with ASBP. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then ASBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
-10.20%
ASBP - SPRO
42%
Loosely correlated
-5.23%
VYGR - SPRO
36%
Loosely correlated
-4.97%
RXRX - SPRO
34%
Loosely correlated
-9.93%
JAGX - SPRO
34%
Loosely correlated
-30.58%
VKTX - SPRO
33%
Loosely correlated
-4.14%
More
Can Spero Therapeutics (SPRO) Stock Reach $5.30?